Lexaria (NASDAQ: LEXX), a global innovator in drug delivery platforms, remains on track to submit an Investigational New Drug (โINDโ) application for its planned U.S. Phase 1b Hypertension Clinical Trial HYPER H23-1. โLexariaโs IND submission builds on five previous human clinical studies conducted from 2018 to 2022 and is integral to the successful filing and review of the submission. These studies were carried out in an aggregate total of 134 healthy and hypertensive persons and evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimensโฆ The company is only aware of a handful of other published research investigating whether a decrease in resting blood pressure is possible following multiple weeks of oral CBD use. Lexaria notes that none of this published research has succeeded in achieving this goal. The outcomes of the companyโs previous research prove DehydraTECH-CBDโs superior power to reduce blood pressure over oral CBD formulations,โ a recent article reads. โThat we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,โ Chris Bunka, CEO of Lexaria, is quoted as saying.
To view the full article, visitย https://ibn.fm/MXl4s
About Lexaria Bioscience Corp.
Lexariaโs patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (โAPIsโ) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, visit the companyโs website atย www.LexariaBioscience.com.
NOTE TO INVESTORS:ย The latest news and updates relating to LEXX are available in the companyโs newsroom atย https://ibn.fm/LEXX
About TinyGems
TinyGemsย is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands withinย theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from TinyGems, text โGemsโ to 844-397-5787 (U.S. Mobile Phones Only)
For more information, please visitย https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published:ย https://www.TinyGems.com/Disclaimer
TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com
TinyGems is powered byย IBN
